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Abstract
Background: Transplantation of vasculogenic progenitor cells (VPC) improves neovascularization after ischemia. However,
patients with type 2 diabetes mellitus show a reduced VPC number and impaired functional activity. Previously, we
demonstrated that p38 kinase inhibition prevents the negative effects of glucose on VPC number by increasing proliferation
and differentiation towards the endothelial lineage in vitro. Moreover, the functional capacity of progenitor cells is reduced
in a mouse model of metabolic syndrome including type 2 diabetes (Leprdb) in vivo.
Findings: The aim of this study was to elucidate the underlying signalling mechanisms in vitro and in vivo. Therefore, we
performed DNA-protein binding arrays in the bone marrow of mice with metabolic syndrome, in blood-derived progenitor
cells of diabetic patients as well as in VPC ex vivo treated with high levels of glucose. The transcriptional activation of ETS
transcription factors was increased in all samples analyzed. Downregulation of ETS1 expression by siRNA abrogated the
reduction of VPC number induced by high-glucose treatment. In addition, we observed a concomitant suppression of the
non-endothelial ETS-target genes matrix metalloproteinase 9 (MMP9) and CD115 upon short term lentiviral delivery of ETS-
specific shRNAs. Long term inhibition of ETS expression by lentiviral infection increased the number of cells with the
endothelial markers CD144 and CD105.
Conclusion: These data demonstrate that diabetes leads to dysregulated activation of ETS, which blocks the functional
activity of progenitor cells and their commitment towards the endothelial cell lineage.
Citation: Seeger FH, Chen L, Spyridopoulos I, Altschmied J, Aicher A, et al. (2009) Downregulation of ETS Rescues Diabetes-Induced Reduction of Endothelial
Progenitor Cells. PLoS ONE 4(2): e4529. doi:10.1371/journal.pone.0004529
Editor: Maurizio Capogrossi, Istituto Dermopatico dell’Immacolata, Italy
Received July 20, 2008; Accepted January 23, 2009; Published February 19, 2009
Copyright: ß 2009 Seeger et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a start-up grant of the University of Frankfurt to FHS and by grants from the Deutsche Forschungsgemeinschaft to JH (HA-
2868/3-3 and SFB728 B5). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: juhae001@uni-duesseldorf.de
¤ Current address: Cell Biology & Molecular Aging Research, IUF (Institut fu¨r Umweltmedizinische Forschung) at the University of Duesseldorf gGmbH,
Duesseldorf, Germany
Introduction
Postnatal vessel formation, known as angiogenesis, was
attributed to the migration and proliferation of preexisting mature
endothelial cells [1,2]. Recent studies demonstrated that circulat-
ing bone marrow-derived endothelial progenitor cells contribute to
adult blood vessel formation, a process characterized as vasculo-
genesis [3]. Endothelial progenitor cells play a major role in repair
processes after myocardial infarction (reviewed in [4]) and wound
healing [5]. However, in vivo and in vitro studies revealed that
endothelial progenitor cells from patients with type 1 and type 2
diabetes were impaired in number and function [5–8].
The molecular mechanisms underlying the reduced endothelial
progenitor cell number and function by high glucose are not yet
clearly defined. Recently, Marchetti et al. demonstrated that high
glucose levels (33 mM) increased apoptosis of endothelial progen-
itor cells in vitro and impaired the PI3-kinase/Akt pathway [9]. In
addition, activation of Akt signalling stimulates the proliferation
and inhibits apoptosis of endothelial progenitor cells cultured
under high-glucose conditions and importantly increases ischemia-
induced mobilization of endothelial progenitor cells [10]. Our
previous study showed that high glucose levels (15 mM) did not
alter apoptosis in endothelial progenitor cells in vitro, but activated
p38 MAP kinase and several downstream targets such as the
transcription factor CREB. Moreover, we found that high glucose
levels decreased endothelial progenitor cell proliferation and
differentiation towards the endothelial cell lineage in vitro [11].
Unfortunately, no animal studies in models for type 2 diabetes or
metabolic syndrome were conducted to identify signalling
mechanisms in vivo which contribute to high glucose-induced
impairment of progenitor cells. One critical issue is to choose an
appropriate mouse model that closely resembles type 2 diabetes in
humans, which is the major form of diabetes and accounts for 95%
of diabetes cases [12]. There are very few animal studies to identify
signalling mechanisms of endothelial progenitor cells in diabetes. It
was shown that NO-mediated impaired mobilization may be
responsible for the progenitor cell reduction in diabetic mice [13].
However, Gallagher et al. used streptozocin-treated mice, a model
not comparable with type 2 diabetes in humans. To study type 2
diabetes in a mouse model we chose the leptin receptor knock out
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mouse model (Leprdb). Leprdb mice lack functional leptin
receptors, become obese shortly after birth and are insulin
resistant and hyperglycemic as adults [14].
The aim of this study was to investigate potential signalling
mechanisms in vasculogenic progenitor cells (VPC), which
regulate the differentiation processes in vitro and in vivo.
ETS (E26 transformation-specific DNA binding domain) is one
of the largest families of transcriptional regulators that share a
highly conserved DNA-binding domain (ETS domain). ETS
transcription factors are downstream of the p38 MAP kinase,
which has already been shown to be important for endothelial
progenitor cell differentiation and proliferation [11]. As ETS
transcription factors are important for proliferation, survival and
differentiation, we hypothesized that this could also be an
important mechanism in VPC (for review see [15]).
We found that ETS DNA-binding activity is much higher in
diabetic cells. Inhibition of the ETS activity leads to increase in
impaired VPC number. Therefore this could be a potential
mechanism to improve the impaired VPC number in patients with
type 2 diabetes.
Methods
Study population and patient characteristics
Mononuclear cells (MNC) were isolated from fresh peripheral
blood of healthy human volunteers or patients with type 2
diabetes.
Written informed consent was obtained from all patients. The
ethics review board of the Hospital of the Johann Wolfgang
Goethe University of Frankfurt, Germany, approved the protocol,
and the study was conducted in accordance with the Declaration
of Helsinki.
Mice
Leptin-receptor-deficient mice (Leprdb mice) were obtained
from Charles River Laboratories and used for the experiments at
an average age of 12 weeks.
The animal studies were approved by the ‘‘Regierungspra¨si-
dium’’ Darmstadt, Germany. All experiments were carried out in
accordance with the ‘‘Position of the American Heart Association
on Research Animal Use’’.
Isolation and Cultivation of VPC
MNC were isolated by density gradient centrifugation with
Biocoll separating solution (Cambrex; 8006g, 20 min, without
brake) from fresh peripheral blood of healthy human volunteers or
patients with type 2 diabetes as previously described [11]. MNCs
(86106 cells/ml medium) were plated on culture dishes coated
with human fibronectin (Sigma) and maintained in endothelial
basal medium (EBM; CellSystems) supplemented with 1 mg/ml
hydrocortisone, 12 mg/ml bovine brain extract, 50 mg/ml genta-
mycin, 50 ng/ml amphotericin B, 10 ng/ml epidermal growth
factor and 20% FCS. After 3 days of culture, more than 90% of
the VPC express endothelial marker proteins KDR, VE-Cadherin
and von Willebrand factor [16–18]. Dual-staining cells positive for
both lectin and 1,19–dioctadecyl–3,3,39,39–tetramethylindocarbo-
cyanine–labelled acetylated low–density lipoprotein (Dil-Ac-LDL)
(Harbor Bio-Products) were judged as VPC [16]. VPC have the
capacity of tube formation in vitro and improve blood flow in
murine models of hindlimb ischemia [19]. Dendritic cell markers
such as CD1a or CD83 were not expressed, however, being early
endothelial progenitors, these cells still bear myeloid and
hematopoietic features, which are lost during further culture into
late outgrowth colonies. Since there is an ongoing debate how to
define endothelial progenitors [20], in particular whether the
expression of hematopoietic lineage-specific markers such as
CD45 precludes endothelial progenitor progeny [21], we decided
to use the term ‘vasculogenic’ (VPC) instead of ‘endothelial’
progenitor cells (EPC) to more emphasize the functional capacity
of these cells than their origin. In some experiments, MNC were
incubated with glucose (Braun Melsungen), mannitol served as
osmotic control. After 3 days in culture, adherent cells were
incubated with Dil-Ac-LDL for 1 hour and 4–5 random power-
fields were counted by independent investigators and with a
computer-based program.
Isolation of Bone Marrow Mononuclear Cells
Bone marrow of animals was harvested by flushing femurs and
tibias with PBS. Mononuclear cells (BMC) were isolated by density
gradient centrifugation using Ficoll (Cambrex; 8006g, 20 min,
without brake). BMC were washed three times with PBS (8006g),
counted and used for the experiments.
Production of lentiviral particles
In order to achieve long term gene silencing, DNA-oligonucle-
otides encoding shRNAs directed against ets1 or ets1 and ets2
were subcloned into pLKO.1-puro (Sigma). Lentiviral particles
were produced in 293T packaging cells using a calcium phosphate
co-precipitation method.
Infection of human MNC
The lentiviral particles were added (1:5) to MNC immediately
after isolation. A second round of infection was performed the next
day and RNA was isolated on day 4. For long term experiments
the number of adherent VPC was determined after staining with
PE-conjugated antibodies against CD105 (BD Biosciences) and
CD144 (BD Biosciences) at day 14 after infection. The biosafety
level 2 experiments were approved by the ‘‘Bezirksregierung’’
Du¨sseldorf.
Protein-DNA binding array
After isolation of cells, nuclear and cytosolic fractions were
separated using a commercially available kit according to the
manufacturer’s protocol (Pierce). Nuclear and cytosolic fractions
were controlled for purity in Western blots with antibodies
directed against the exclusively nuclear or cytosolic proteins
Topoisomerase I (nuclear) and Hsp70 (cytosolic) as described
previously [22]. Protein/DNA arrays were performed according to
the manufacturer’s protocol (Panomics, USA). Briefly, 25 mg of
nuclear extract was incubated with the biotinylated TranSignalH
Probe Mix. DNA/protein complexes were washed. Then, DNA
was separated from protein and hybridized on the membranes at
42uC. The bound biotinylated DNA probes were detected using
streptavidin coupled horseradish peroxidase and a luminogenic
peroxidase substrate (ECL). Signals were detected using ECL-
Hyperfilm (Amersham, Germany) and semiquantitative analysis
was performed using the Tina-software 2.09 (Raytec). As suggested
by the manufacturer the local area surrounding the individual
spots was used for background subtraction. The membranes
contain prespotted binding sites for various transcription factors in
duplicate and two different dilutions annotated by the manufac-
turer, three of which belong to the ETS family (ETS, ETS/PEA3,
EGR). According to genecards (www.genecards.org) these proteins
are defined as follows: ETS: v-ets erythroblastosis virus E26
oncogene homolog (avian), ETS/PEA3: ets variant gene 4
(ETV4), EGR: early growth response. ‘‘ECL spots’’ are positive
controls on the membrane and, according to the manufacturers
ETS Reduces VPC
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specifications, can be used to normalize signal intensities.
Therefore, after calculating the density of the spots using Tina
software, the membranes were normalized to the average of their
‘‘ECL spot density’’ (average of all ECL spots). Only binding sites
were the densitometric analysis of duplicate spots and the
corresponding dilutions yielded the same results were analyzed
in more detail.
Real-time RT(reverse transcriptase)-PCR
Gene-specific mRNA expression was determined by real-time
RT-PCR. RNA concentration was determined photometrically
and aliquots of total RNA (2 mg) were used for cDNA-synthesis
with the SuperscriptTM III First-Strand synthesis system for RT-
PCR (Invitrogen, Karlsruhe, Germany). PCR reactions were
carried out on an Abi Prism 7000 (Applied Biosystems, Foster
City, CA, USA) using SYBRGreen PCR Master Mix (Applied
Biosystems, Darmstadt, Germany). For relative expression com-
parison between different cells the DDCT method was used,
utilizing the 18S RNA as housekeeping gene. Primers were
designed using the online-software Primer3. The following primer
pairs were used:
18S RNA: GCCGCTAGAGGTGAAATTCTTG,
CATTCTTGGCAAATGCTTTCG
CD105: CAACTGTGTGAGCCTGCTGT, GACAGGT-
CAGGGCTGATGAT
CD115: ATGGTCATGTGGCCAAGATT, GAGGATGC-
CATAGGACCAGA
ETS1: GAGTCAACCCAGCCTATCCA, CCGAGGGG-
TAGTCATTCTCA
ETS2: TCTGGTGAACGTGAATCTGC, CGGAGGT-
GAGGTGTGAATTT
MMP9: TTGACAGCGACAAGAAGTGG, GCCATT-
CACGTCGTCCTTAT
Statistical analysis
Data are expressed as mean6SEM from at least 3 independent
experiments unless stated otherwise. For in vitro data, statistical
analysis was performed by a two-sided student t test. Statistical
significance was assumed at a value of p,0.05.
Results
Induced activation of ETS transcription factors in Leprdb
mice
Because diabetes leads to impairment in number and functional
activity of progenitor cells in patients [7,8,16], we wanted to
elucidate the potential underlying signalling mechanisms. There-
fore, we performed DNA-protein binding arrays with bone
marrow-derived mononuclear cells from Leprdb mice and
compared them to their wild type littermates. Out of 450
transcription factors, the activity of ETS transcription factors
was significantly increased in BMC of Leprdb mice compared to
the wild type littermates (Figure 1). Similarly, we found an increase
in ETS1 protein expression in BMC of Leprdb mice (data not
shown).
Activation of ETS transcription factors under
hyperglycemic conditions in vitro as well as in patients
with type 2 diabetes
To further investigate that protein-DNA-binding activity of
ETS transcription factors occurs also in humans, we first isolated
human peripheral blood mononuclear cells and cultivated the cells
for 4 days in the presence or absence of high glucose (15 mM).
DNA-protein binding arrays were performed and, similar as in
Leprdb mice, ETS transcription factors were activated under high
glucose culturing conditions (Figure 2). Having demonstrated that
high glucose enhanced DNA-binding activity of ETS transcription
factors, we next examined ETS DNA-binding activity in
Figure 1. ETS-DNA-protein binding activity in BMC of Leprdb
mice. DNA-binding activity of ETS family proteins in BMC of Leprdb
mice and their age-matched littermates was analyzed by the use of
precoated membranes (Panomics). In all cases 25 mg of nuclear extracts
were used. Representative membranes of n = 3 experiments are shown.
doi:10.1371/journal.pone.0004529.g001
Figure 2. ETS-family DNA-binding activity in VPC after ex vivo
glucose stimulation. Mononuclear cells were cultivated in EBM as
described in the presence or absence of 15 mM glucose. DNA binding
of different transcription factors was analyzed by the use of precoated
membranes (Panomics). In all cases 25 mg of nuclear extracts were used.
Representative membranes of n = 3 experiments are shown, *p,0.05 vs.
control.
doi:10.1371/journal.pone.0004529.g002
ETS Reduces VPC
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peripheral blood-derived VPC from healthy volunteers as well as
patients with type 2 diabetes (for characteristics see table 1).
Indeed, ETS-DNA binding activity is increased in patients with
type 2 diabetes compared to healthy volunteers (Figure 3). Of note,
this difference was obtained after 3 days of culture under similar
conditions.
Ablation of ETS1 expression by siRNA rescued high
glucose-induced reduction of progenitor cell number
To demonstrate a causal link between ETS transcription factors
and the reduced number of progenitor cells in type 2 diabetes, we
transfected peripheral blood-derived mononuclear cells with
control siRNA or siRNA against ETS1 and incubated them with
high glucose for 3 days. High glucose levels induced a significant
reduction of adherent VPC when transfected with control siRNA
(Figure 4). In contrast, in cells transfected with ets1 siRNA the
negative effect of high glucose levels on VPC number was
abrogated (Figure 4).
Downregulation of ETS transcription factors suppressed
non-endothelial ETS-target genes MMP9 and CD115 and
increased long term endothelial lineage commitment of
VPC
In the next set of experiments, we wanted to elucidate whether
knock down of ETS transcription factors has an influence on the
differentiation capacity of MNC. Therefore, we designed lentiviral
shRNA vectors to permanently knock down ETS1 or ETS1 and
ETS2 expression. Indeed, short term lentiviral knockdown of ETS1
expression resulted in a concomitant suppression of the known non-
endothelial ETS-target genes MMP9 and CD115 [23] and an
increase in the endothelial marker CD105 (Figure 5A). Knockdown
with a more potent shRNA virus targeting ETS1 and ETS2
completely abolished expression of MMP9 and CD115 (Figure 5B).
Strikingly, knockdown of ETS transcription factors over two weeks
led to a stong increase in CD105- and CD144-positive adherent
cells (Figure 5C). The effect on CD105 positive cells was even more
pronounced, when we knocked down both ETS1 and ETS2, clearly
demonstrating a shift towards endothelial lineage commitment of
peripheral blood derived mononuclear cells.
Figure 3. ETS in VPC of subjects with type 2 diabetes. DNA-binding activity of different transcription factors in ex vivo cultivated VPC of
healthy controls and patients with type 2 diabetes was analyzed by the use of precoated membranes (Panomics). In all cases 25 mg of nuclear extracts
were used. Representative membranes of n = 3 experiments are shown.
doi:10.1371/journal.pone.0004529.g003
Table 1.
Healthy Diabetes p-value
(n =4) (n =4)
age (years) 5665 62616 n.s.
gender (% male) 50 50 n.s.
hypertension (%) 0 75 p,0.05
smoker (%) 25 25 n.s.
diabetes (%) 0 100 p,0.05
insulin (%) 50
oral therapy (%) 50
HbA1c (%) 5.860.1 7.561.0 p,0.05
doi:10.1371/journal.pone.0004529.t001
ETS Reduces VPC
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Discussion
The data of the present study demonstrate that increased
nuclear DNA-binding activities of ETS1 and ETS2 transcription
factors are crucial determinants of diabetes- and high glucose-
induced reduced number of VPC. Moreover, increased DNA-
binding activity of ETS-transcription factors inhibits the commit-
ment of progenitor cells towards the endothelial cell lineage.
Emerging evidence indicates that endothelial progenitor cells
are involved in the maintenance of vascular homeostasis and their
impairment may be conducive to vascular disease. Endothelial
progenitor cell function is impaired in patients with coronary
artery disease and diabetes [7,16]. Recently, Fadini et al. suggested
that diabetes is the most relevant risk factor associated with a
reduction of endothelial progenitor cells [5,6]. However, the
underlying mechanisms are still not understood. Marchetti et al
investigated the effects of high glucose toxicity (33 mM) on
endothelial progenitor cells and determined that high glucose
reduced phosphorylation of Akt and thereby increased activation
and nuclear localization of the forkhead transcription factor-1
previously shown to have negative impact on endothelial function
[24]. Our study now provides evidence that in vivo and in vitro the
number of VPC is reduced in conditions of type 2 diabetes and
that one major signalling pathway involved is the activation of the
transcription factors ETS1 and ETS2.
The ETS protein family is a group of transcription factors that
share a DNA-binding ETS domain and regulate the expression of a
variety of genes including key ones involved in regulation of cell
proliferation, differentiation and survival. Because of their critical role
in basic cellular processes, dysregulation of ETS transcription factors
can be found in many human diseases with the need for
neovascularisation, such as cancer. ETS transcription factors have
been implicated in the regulation of genes involved in homeostasis,
vascular development and angiogenesis [15], even though no
endothelial specific ETS transcription factor has been identified by
now.
We could clearly show that ETS dysregulation by high levels of
glucose leads to impairment of progenitor cell number as well as
functional capacity. The importance of circulating endothelial
progenitor cell number, measured as CD34+KDR+ cells in the
peripheral blood, has recently been shown as these cells predict the
outcome in CAD-patients [25,26].
Although the transcription factor ETS reduces VPC numbers,
ETS activity is clearly important in adult angiogenesis [27,28]. In
the resting endothelium, ETS1 is expressed at a very low level.
During angiogenesis, re-endothelialisation after balloon denuda-
tion in a rat model as well as in scratch wound migration assays,
ETS1 is transiently expressed at high levels in endothelial cells
[29,30], suggesting that during the process of vessel formation or
repair upregulation of ETS1 transcription factor expression is
required in mature endothelial cells. However, the process of
preexisting mature endothelial cells to perform angiogenesis differs
completely from VPC-induced vasculogenesis or vascular repair of
the damaged endothelial layer.
Even though our findings demonstrate the importance of ETS1
in angiogenesis, ETS1 deficient mice develop normally except for
an increased perinatal mortality [31,32]. Especially no vascular
phenotype can be detected. Therefore, we hypothesized that most
likely other ETS transcription factors can compensate for its loss.
Alternatively, these mice might have increased numbers and
improved functionality of their endothelial progenitor cells for
compensation.
Members of the ETS gene family are known to be expressed in
the hematopoietic tissue and some of them play a pivotal role in
hematopoietic cell development. The special importance of ETS1
regulation in differentiation of hematopoietic stem cells has
previously been shown. During erythroid differentiation, ETS1 is
downregulated and exported out of the nucleus. In contrast,
during megakaryopoiesis, ETS1 increases and remains in the
nucleus [33–36]. Similarly, it seems that ETS1 activation is
required for angiogenesis by sprouting of mature endothelial cells
and down-regulation of ETS DNA binding activity is required for
increased VPC differentiation from their progenitors as shown in
this study.
We clearly showed that glucose upregulates ETS DNA binding
activity and thereby reduces VPC numbers. In addition, it has
been shown that other pro-inflammatory stimuli/cardiovascular
risk factors such as TNFa up-regulate ETS transcription factors
[37] and reduce the number of endothelial progenitor cells [11].
Therefore, it is tempting to speculate that not only high glucose
but also TNFa prevents endothelial cell lineage commitment by
ETS transcriptions factor activation.
Taken together, the present study demonstrates a critical role
for ETS transcription factors on VPC number and function. In
Figure 4. ETS1 knockdown counteracts high-glucose induced reduction of VPC numbers. Mononuclear cells were transfected with ETS1-
specific siRNA (ets1), a scrambled control (scr) at day 0 or left untransfected and stimulated with glucose. After 3 days of culture, VPC were stained
and counted by independent investigators (left side). Data are mean6SEM of n$6; *p,0.05 vs. control. ETS1 protein expression was examined by
immunoblot analysis (right side). Actin was used as loading control.
doi:10.1371/journal.pone.0004529.g004
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Figure 5. ETS knockdown suppresses expression of non-endothelial ETS target genes and induces CD105 and CD144. Mononuclear
cells were infected with lentiviruses expressing shRNAs targeting ETS1 (ets1) or ETS1 and ETS2 (ets1/2) or the corresponding scrambled shRNA
controls (scr1, scr1/2). (A+B) After 4 days of culture RNA was prepared, and real-time RT-PCR was performed. Expression was normalized to 18S RNA
and is shown relative to RNA isolated from cells transduced with a virus expressing the corresponding scrambled shRNA (scr). (A) ets1 knockdown, (B)
ets1/2 knockdown. (C) After 12 days of culture, adherent VPC were stained with CD105 and CD144 antibodies and positive cells were counted. The
upper part shows representative images, the lower part shows the quantification of the data of n= 4 experiments. Data are mean6SEM. *p,0.05 vs.
scr, **p,0.05 vs. ets1.
doi:10.1371/journal.pone.0004529.g005
ETS Reduces VPC
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vitro and in vivo high glucose levels increased ETS DNA-binding
and thus most likely transcriptional activity. Inhibition of ETS1
and ETS2 expression counteracts the reduction of VPC number
by enhancing endothelial lineage commitment. Given the fact that
ETS transcription factors regulate a plethora of genes [23], a
systematic analysis of other downstream targets besides CD115,
MMP9, CD144 and CD105 investigated here is required to fully
understand the role of the ETS family in the cardiovascular
system.
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